PDF下载 ( 287 KB)
The effect of cimetidine on the blood sugar, serum insulin and other indexes in NASH rats
-
摘要: 探讨非酒精性脂肪性肝炎（NASH）大鼠经甲氰咪胍治疗后肝微粒体CYP450、CYP2E1含量、血糖、胰岛素等指标的变化。将30只雄性SD大鼠随机分为对照组（n=10）、模型组（n=10）和治疗组（n=10）,治疗组给予甲氰咪胍200mg.kg-1.d-1灌胃,饲养12周,分别于实验第4、6、8、10、12周采用剪尾取血法取血,前四次取血测定血糖、AST、ALT含量,最后一次处死大鼠后取血测定血糖、胰岛素、肝功、血脂、CYP450及CYP2E1含量,观察肝组织学特点。观察到模型组大鼠肝功、血糖指标升高,并随实验进展更加明显;治疗组CYP450、CYP2E1、ALT、AST含量均低于模型组（P<0.05）,且大鼠的肝细胞损害明显减轻,但其余指标无显著差异。可见甲氰咪胍能够减轻NASH大鼠肝细胞损害,抑制CYP450、CYP2E1表达,改善肝功水平,不能改善胰岛素抵抗,及降低血糖、血脂。Abstract: To study the effect of cimetidine on cytochrome P450, CYP2E1, blood sugar, insulin and othert indexes in nonalcoholic steatohepatitis (NASH) rats.30 male SD rats were randomly divided into three groups, control group (n=10) , model group (n=10) and therapeutic group (n=10) .The therapeutic group received cimetidine 200mg daily for 12 weeks.The rats were taken the blood by cutting tails at the 4th, 6th, 8th, 10th and 12th weeks during the study.In the first 4 times, the level of serum AST, ALT and blood sugar was measured.And at the last time, CYP450, CYP2E1, blood sugar, insulin, ALT, AST, TG, TC, LDL, and HDL were measured.We also observe the histologic characters of NASH rats.We observed the levels of ALT, AST, blood sugar in model group increased significantly, then kept increasing through the study.The decrease of CYP450, CYP2E1 in therapeutic groups was obvious.There was an obvious difference of ALT, AST between therapeutic group and model group, while the other indexes be not obviously distinguished from each other.The hepatic injury in therapeutic groups was significantly lessened.So cimetidine can prevent nonalcoholic hepatic injury, inhibit the expressions of CYP450 and CYP2E1, and decrease the expression of ALT and AST, but have no effect on blood sugar, insulin, TG, TC and lipoprotein.
-
Key words:
- cimitidine /
- nonalcoholic steatohepatitis /
- cytochrome P450 /
- insulin resistance /
- hepatic function /
- blood fat
-
[1]Day CP.Nonalcoholic steatohepatitis (NASH) :where are we nowand where are we going?[J].Gut, 2002, 50∶585-588. [2]Marchesini G, Forlani G.NASH:from liver diseases to metabolicdisorders and back to clinical hepatology[J].Hepatology, 2002, 35∶497-499. [3]范建高, 丁晓东, 曾说.非酒精性脂肪性肝炎:美国肝脏病学会专题研讨会纪要[J].肝脏, 2003, 8 (2) ∶59-61. [4]朱曼, 王睿, 张永清, 等.大鼠肝微粒体细胞色素P450酶系检测方法学研究[J].中国临床药理学与治疗学, 2004, 9 (5) ∶500-503. [5]尤鹏.非酒精性脂肪肝炎发病机制的研究进展[J].中国医药导刊, 2003, 5 (2) ∶97-99. [6]Rashid A, Wu T, Huang C, et al.Mitochondrial proteins that regu-late apoptosis and necrosis are induced in mouse fatty liver[J].Hep-atology, 1999, 29∶1131-1138. [7]Bugianesi E, Manzini P, D'Antico S, et al.Relative contribution ofiron burden, HFE mutations, and insulin resistance to fibrosis innonalcoholic fatty liver[J].Hepatology, 2004, 39∶179-187. [8]Rao MS, Reddy JK.Peroxisomal beta-oxidation and steatohepatitis[J].Semin Liver Dis, 2001, 21 (1) ∶43-55. -
本文二维码
计量
- 文章访问数: 2128
- HTML全文浏览量: 15
- PDF下载量: 794
- 被引次数: 0
下载:
